I'm initiating SELLAS Life Sciences (SLS) with a "Hold" rating. The reason why I'm giving this biotech this rating is because it is in the process of developing its WT1-targeting immunotherapeutic ...
The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD. In part 2 of an interview ...
— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced the successful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results